News
CRMD
7.10
-2.74%
-0.20
Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates
NASDAQ · 20h ago
Weekly Report: what happened at CRMD last week (0803-0807)?
Weekly Report · 2d ago
Cormedix Wins Preliminary OK on Governance Settlement Reforms
TipRanks · 5d ago
U.S. District Court Granted Preliminary Approval Of CorMedix Derivative Settlement On July 24; Final Hearing Set For September 23
Benzinga · 5d ago
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates
NASDAQ · 08/04 21:15
Weekly Report: what happened at CRMD last week (0727-0731)?
Weekly Report · 08/03 09:29
Top profitable small caps trading at bargain P/E multiples during Q2 earnings
Seeking Alpha · 07/27 13:09
Weekly Report: what happened at CRMD last week (0720-0724)?
Weekly Report · 07/27 09:30
Weekly Report: what happened at CRMD last week (0713-0717)?
Weekly Report · 07/20 09:29
As Q2 earnings kick off, these small-cap stocks earn an A+ for profitability
Seeking Alpha · 07/17 17:06
Frequency Electronics Posts Weak Q4 Results, Joins AST SpaceMobile And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
Benzinga · 07/16 12:02
Weekly Report: what happened at CRMD last week (0706-0710)?
Weekly Report · 07/13 09:30
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates
NASDAQ · 07/09 21:25
Exelixis, Inc. (EXEL) Hit a 52 Week High, Can the Run Continue?
NASDAQ · 07/08 13:15
CorMedix Is Maintained at Outperform by RBC Capital
Dow Jones · 07/07 16:21
CorMedix Price Target Cut to $13.00/Share From $14.00 by RBC Capital
Dow Jones · 07/07 16:21
RBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $13
Benzinga · 07/07 16:11
The Math Shows IHE Can Go To $110
NASDAQ · 07/07 11:35
Weekly Report: what happened at CRMD last week (0629-0703)?
Weekly Report · 07/06 09:31
Cormedix Restructures Leadership, Expands Operating and Commercial Role
TipRanks · 07/02 21:07
More
Webull provides a variety of real-time CRMD stock news. You can receive the latest news about Cormedix through multiple platforms. This information may help you make smarter investment decisions.
About CRMD
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.